Tim Platt/DigitalVision via Getty Images Thesis Viking Therapeutics (NASDAQ:VKTX) is a biotechnology company in the clinical stage focused on the discovery and development of novel treatments for metabolic and endocrinology disorders. Viking's most promising program is VK2735, a dual agonist (activator) of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is aimed for the treatment of obesity, and it accounts for two formulations currently being tested ...